Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase 3 6Phase NA 3Phase 1 3Phase 4 1

Status

Terminated 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3Other neoplasm 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 69Lymphoma 20Lymphoma, Mantle-Cell 19Leukemia, Myeloid, Acute 17Leukemia, Lymphocytic, Chronic, B-Cell 17Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Lymphoma, Non-Hodgkin 15Neoplasms, Plasma Cell 14Lymphoma, Large B-Cell, Diffuse 14Lymphoma, Follicular 13Lymphoma, B-Cell, Marginal Zone 12Unspecified Adult Solid Tumor, Protocol Specific 10Hodgkin Disease 10Lymphoma, Large-Cell, Anaplastic 9Immunoblastic Lymphadenopathy 9Waldenstrom Macroglobulinemia 8Recurrence 8Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Leukemia 8Burkitt Lymphoma 8Myelodysplastic Syndromes 7Lymphoma, T-Cell, Cutaneous 7Head and Neck Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Sezary Syndrome 6Neoplasms 6Mycosis Fungoides 6Lymphoma, Large-Cell, Immunoblastic 6Congenital Abnormalities 6Breast Neoplasms 6

Interventions

Dexamethasone 7Calcium Dobesilate 5Filgrastim 4Cyclophosphamide 4miridesap 3ixazomib 3dexamethasone acetate 3dexamethasone 21-phosphate 3auricularum 3Peripheral Blood Stem Cell Transplantation 3Bortezomib 3venetoclax 2Tacrolimus 2Methylprednisolone 2Amifostine 2sargramostim 1pyroxamide 1pomalidomide 1nelarabine 1melflufen 1isatuximab 1fludarabine phosphate 1daratumumab 1X-Rays 1Topotecan 1Tetradecanoylphorbol Acetate 1Technetium Tc 99m Pyrophosphate 1Technetium 1Sunitinib 1Specimen Handling 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Immunoglobulin Light-chain Amyloidosis × Bortezomib × Clear all
NCT04754945 2026-02-18

Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis

Emory University

Phase 1 Active not recruiting
11 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT01728259 2023-05-09

First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD

Barbara Ann Karmanos Cancer Institute

Phase 1 Terminated
18 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT00006362 2011-08-03

PS-341 in Treating Patients With Advanced Cancer

Mayo Clinic

Phase 1 Completed
LymphoidOther hematologic neoplasmOther neoplasmPlasma cell

Immunoglobulin Light-chain Amyloidosis, Burkitt Lymphoma, Leukemia, Leukemia, Hairy Cell, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Precancerous Conditions, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡